Antifibrotic Agents in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Ji Hoon JangJunghae KoSo Young JungDae-Wook KimJu Hyun Oh Tae-Jung Kim Joo Hun ParkMiyoung ChoiJae Ha Lee

Published in: Life (Basel, Switzerland) (2023)

The meta-analysis suggests that nintedanib and pirfenidone may have clinical utility in reducing disease progression in patients with RA-ILD. Further research is needed to confirm the clinical benefits of antifibrotic agents in RA-ILD.

Keyphrases

interstitial lung disease
rheumatoid arthritis
idiopathic pulmonary fibrosis
pulmonary fibrosis
systemic sclerosis
systematic review
disease activity
meta analyses
ankylosing spondylitis
randomized controlled trial